Items where Subject is "EGFR"

B

Bell, D. W., Brannigan, B. W., Matsuo, K., Finkelstein, D. M., Sordella, R., Settleman, J., Mitsudomi, T., Haber, D. A. (July 2008) Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clinical Cancer Research, 14 (13). pp. 4079-84. ISSN 1078-0432

Bell, D. W., Gore, I., Okimoto, R. A., Godin-Heymann, N., Sordella, R., Mulloy, R., Sharma, S. V., Brannigan, B. W., Mohapatra, G., Settleman, J., Haber, D. A. (December 2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics, 37 (12). pp. 1315-6. ISSN 1061-4036

Berger, A. H., Chen, M., Morotti, A., Janas, J. A., Niki, M., Bronson, R. T., Taylor, B. S., Ladanyi, M., Van Aelst, L., Politi, K., Varmus, H. E., Pandolfi, P. P. (2013) DOK2 inhibits EGFR-mutated lung adenocarcinoma. PLoS One, 8 (11). e79526. ISSN 1932-6203

G

Gholami, Sepideh, Grothey, Axel (March 2020) EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit? The Lancet Oncology, 21 (3). pp. 324-326. ISSN 1470-2045

H

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., Settleman, J. (2005) Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 70. pp. 419-26. ISSN 0091-7451

K

Klingler, S., Guo, B., Yao, J., Yan, H., Zhang, L., Vaseva, A. V., Chen, S., Canoll, P., Horner, J. W., Wang, Y. A., Paik, J. H., Ying, H., Zheng, H. (May 2015) Development of resistance to EGFR targeted therapy in malignant glioma can occur through EGFR dependent and independent mechanisms. Cancer Research, 75 (10). pp. 2109-2119. ISSN 0008-5472

Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., Rabindran, S. K., McGinnis, J. P., Wissner, A., Sharma, S. V., Isselbacher, K. J., Settleman, J., Haber, D. A. (May 2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences of the United States of America, 102 (21). pp. 7665-70. ISSN 0027-8424

L

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., Haber, D. A. (May 2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine, 350 (21). pp. 2129-39. ISSN 1533-4406 (Electronic)

M

McFadden, D. G., Politi, K., Bhutkar, A., Chen, F. K., Song, X., Pirun, M., Santiago, P. M., Kim-Kiselak, C., Platt, J. T., Lee, E., Hodges, E., Rosebrock, A. P., Bronson, R. T., Socci, N. D., Hannon, G. J., Jacks, T., Varmus, H. (October 2016) Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc Natl Acad Sci U S A, 113 (42). E6409-E6417. ISSN 1091-6490 (Electronic)0027-8424 (Linking)

Miranti, C. K., Bill, H. M., Modres, S. L., Rao, V. R., Knudsen, B., Muthuswamy, S. K., Brugge, J. S. (March 2003) Integrin-induced EGFR activation and control of the cell cycle in epithelial cells. Faseb Journal, 17 (5). A974-A974. ISSN 0892-6638

Mulloy, R., Ferrand, A., Kim, Y., Sordella, R., Bell, D. W., Haber, D. A., Anderson, K. S., Settleman, J. (March 2007) Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Research, 67 (5). pp. 2325-30. ISSN 0008-5472

Määttä, J. A., Sundvall, M., Junttila, T. T., Peri, L., Laine, V. J. O., Isola, J., Egeblad, M., Elenius, K. (2006) Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Molecular Biology of the Cell, 17 (1). pp. 67-79. ISSN 10591524 (ISSN)

S

Sordella, R., Bell, D. W., Haber, D. A., Settleman, J. (August 2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 305 (5687). pp. 1163-7. ISSN 1095-9203 (Electronic)

Stahlhut, C., Slack, F. J. (July 2015) Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle, 14 (13). pp. 2171-80. ISSN 1551-4005 (Electronic)1551-4005 (Linking)

W

Wang, L., Liang, B., Zhong, Y. (September 2013) Reduced EGFR level potentially mediates the A beta 42-induced neuronal loss in transgenic fruit fly and mouse. Protein & Cell, 4 (9). pp. 647-649. ISSN 1674-800X

Y

Ying, H. Q., Zheng, H. W., Scott, K., Wiedemeyer, R., Yan, H. Y., Lim, C., Huang, J., Dhakal, S., Ivanova, E., Xiao, Y. H., Zhang, H. L., Hu, J., Stommel, J. M., Lee, M. A., Chen, A. J., Paik, J. H., Segatto, O., Brennan, C., Elferink, L. A., Wang, Y. A., Chin, L., DePinho, R. A. (April 2010) Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 107 (15). pp. 6912-6917. ISSN 0027-8424